Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CC 94676

Next Previous
Drug Profile

CC 94676

Alternative Names: AR-LDD; BMS-986365; CC-94676

Latest Information Update: 26 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Class Antineoplastics
  • Mechanism of Action Androgen receptor degradation enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer
  • Phase I Solid tumours

Most Recent Events

  • 13 Mar 2025 Phase-III clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in Australia (PO) (NCT06764485)
  • 19 Feb 2025 Celgene completes a phase I trial for pharmacokinetic and bioavailability study (In volunteers) in USA (PO, Capsule) (NCT06417229)
  • 08 Jan 2025 Celgene plans the phase III rechARge trial for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Czeche Republic, Denmark, France, Germany, Ireland, Italy, South Korea, Poland, Puerto Rico, Romania, Slovakia, Spain, Sweden, Taiwan, Turkey, United Kingdom, in March 2025 (NCT06764485)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top